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Abstract
Uncertainties in understanding all potential modes-of-action for asthma induction and elicitation 
hinders design of hazard characterization and risk assessment methods that adequately screen and 
protect against hazardous chemical exposures. To address this challenge and identify current 
research needs, the University of Cincinnati and the American Cleaning Institute hosted a webinar 
series to discuss the current state-of-science regarding chemical-induced asthma. The general 
consensus is that the available database, comprised of data collected from routine clinical and 
validated toxicological tests, is inadequate for predicting or determining causal relationships 
between exposures and asthma induction for most allergens. More research is needed to 
understand the mechanism of asthma induction and elicitation in the context of specific chemical 
exposures and exposure patterns, and the impact of population variability and patient phenotypes. 
Validated tools to predict respiratory sensitization and to translate irritancy assays to asthma 
potency are needed, in addition to diagnostic biomarkers that assess and differentiate allergy 
versus irritant-based asthmatic responses. Diagnostic methods that encompass the diverse 
etiologies of asthmatic responses and incorporate robust exposure measurements capable of 
capturing different temporal patterns of complex chemical mixtures are needed. In the absence of 
ideal tools, risk assessors apply hazard-based safety assessment methods, in conjunction with 
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active risk management, to limit potential asthma concerns, proactively identify new concerns, and 
ensure deployment of approaches to mitigate asthma-related risks.
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Introduction
The increasing prevalence of asthma in the United States, and worldwide, is a growing 
burden on health care costs and quality of life (CDC, 2015). Numerous epidemiological 
studies and reviews have suggested a link between the use of cleaning products in residential 
and commercial settings to an increase in risk of physician-diagnosed asthma (Jaakkola and 
Jaakkola, 2006; Nielsen et al., 2007; Quirce and Barranco, 2010; Zock, 2005; Zock et al., 
2010; Rosenman, 2003), however a causal link between exposure and response is unclear, in 
part due to poor characterization of the complex mixtures to which cleaners are exposed 
(Vincent et al., 2017). The multiple phenotypes and causes of disease and response 
elicitation hamper the ability to design hazard characterization and risk assessment methods 
that adequately screen and protect against chemical exposures (Maier et al., 2014, 2015; 
Vincent et al., 2017).
To address these challenges and identify current research needs regarding chemical-related 
asthma, the University of Cincinnati hosted a multipart webinar series from February 25th to 
October 21st, 2016 in conjunction with the American Cleaning Institute (ACI) to discuss the 
current state of science regarding chemical-induced asthma. Key issues and research 
opportunities were described in the context of five presentations. These presentations are 
available online1. The results of the effort are summarized to guide development of safety 
and risk assessment approaches and address uncertainties and data gaps in asthma-related 
disease as it pertains to chemical product exposures.
Clinical Perspectives in Evaluating Chemical-Induced Asthma
Asthma pathophysiology is heterogeneous, but can be generally divided into smooth muscle 
dysfunction (characterized by bronchoconstriction, bronchial hyperreactivity, hypertrophy or 
hyperplasia, and inflammatory mediator release) and airway inflammation (characterized by 
inflammatory cell infiltration/activation, mucosal edema, cellular proliferation, epithelial 
damage, and basement membrane thickening) pathways (Bousquet et al., 2000). All of these 
pathophysiological changes ultimately result in asthma symptoms. Asthma-related 
inflammation can also be considered as an acute response often followed by a chronic 
response where immediate bronchoconstriction, swelling, increased secretions and cough 
can lead to a chronic inflammation phase associated with cell recruitment, epithelial 
damage, airway remodeling with cellular proliferation, and extracellular matrix changes that 
can eventually lead to fixed airway obstruction if not treated.
1http://www.med.uc.edu/eh/centers/rsc/education/webinars/asthma
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In addition to pathophysiologic differences in asthma response, the molecular underpinnings 
of the disease are also variable. Mechanisms related to sensitization arise when allergens 
trigger immunoglobulin E (IgE)-mediated pathways which lead to airway inflammation. T 
cells, in addition to other effector cells (e.g., mast cells, eosinophils, dendritic cells), play an 
important role by producing an array of cytokines that contribute to acute symptoms and 
perpetuate chronic inflammation. Irritant-induced asthma (i.e., reactive airways dysfunction 
syndrome), however, involves a different, less-understood mechanistic pathway. Irritants 
cause disruption of the airway epithelium and activate different regulating molecules and 
cytokines that can also trigger the migration of effector cells into the lungs leading to release 
of cytokines and mediators. There may be cross talk between allergic and non-allergic 
mechanistic pathways as many patients with asthma are affected by allergic and non-allergic 
triggers. In fact, a recent study that reclassified chronic rhinitis patients with a physician 
diagnosis of allergic, mixed (allergic and non-allergic triggers) or non-allergic rhinitis using 
an irritant index scale found that a significant percentage of patients previously diagnosed 
with allergic rhinitis actually had mixed rhinitis. Furthermore, these mixed rhinitis patients 
with a high irritant index score had a greater prevalence of physician diagnosed asthma 
suggesting that chemical irritants in conjunction with allergen triggers compared to allergen 
triggers alone may contribute to disease severity (Bernstein et al., 2012).
Mixed mechanistic pathways can complicate the assessment of chemical exposure causality. 
Although there are multiple biomarkers such as peripheral or sputum eosinophils, exhaled 
nitric oxide, total IgE levels and urinary leukotrienes that can be measured to characterize 
different asthma endotypes2, their application as specific predictive indicators of chemical 
induced asthma requires further understanding of the mechanistic pathways for this 
condition. An irritant index questionnaire, similar to the one used to assess non-allergic 
triggers in chronic rhinitis patients, previously was used to demonstrate that increased 
irritant index scores correlated with increased bronchial airway hyperresponsiveness (Brooks 
et al., 1990). Although this clinical tool may be useful for assessing irritant-induced asthma 
qualitatively and quantitatively, this instrument depends on patient recall and exposure 
opportunity which introduces bias into the responses and thus has some inherent limitations 
for assessing chemical exposures and related health effects especially as they pertain to 
asthma. Another potential biomarker is periostin, which is a ligand for various integrins, 
important for cell adhesion and migration of epithelial cells. Finally, the nasal tissue, which 
is much more easily accessible than obtaining induced sputum, bronchial alveolar lavage, or 
lung tissue biopsies, could be used as a surrogate for identifying biomarkers that could 
predict inflammatory responses in the lower respiratory tract, specifically by looking at 
mRNA transcriptomes and translational proteins in response to chemical triggers.
In the absence of a reliably diagnostic biomarker, a variety of traditional approaches are 
more commonly used to diagnose and assess patients with asthma. Risk factors for asthma 
include atopy, family history, passive/active smoke exposure, early childhood bronchiolitis, 
eczema, childhood persistent wheeze, and a number of environmental determinants. Factors 
such as frequent use of antibiotics and breast feeding may also protect against or promote 
2An endotype is a subtype of disease or condition. Endotypes of asthma, for example, would include allergic and non-allergic asthma.
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the progression to asthma, based on their effects on the gastrointestinal microbiome. 
However, there is much we still do not understand regarding asthma risk factors and the 
variable and heterogeneous nature of this disease.
In diagnosing asthma, the clinician needs to consider the course of the disease (management 
history), what a typical episode involves, previous treatments, environmental and social 
settings, family history, allergy history, occupational history, patterns of symptoms (e.g., 
episodic vs. persistent, nocturnal, seasonal), and the types of triggers. Obtaining an 
occupational history is extremely important since up to approximately 15% of asthma cases 
may be caused by workplace exposures (AAAAI, 2017). Occupational exposures associated 
with asthma are characterized as inciters (i.e., irritants with moderate to high levels of 
exposure that exacerbate asthma) or inducers (i.e., sensitizing allergens or irritants that cause 
new-onset asthma). In contrast to occupational asthma induced by a sensitizing agent, there 
is generally no latency period associated with irritant-induced occupational asthma (e.g., 
Reactive Airways Dysfunction Syndrome, or RADS). After discovering a suspected 
occupational cause of asthma through patient history, it is important to request Safety Data 
Sheets (SDS) to identify and/or confirm suspected exposures. A survey by Bernstein and 
Shusterman (2010) indicated that a third of physicians who treated patients with 
disinfectant-related asthma symptoms had difficulty obtaining chemical information (e.g., 
product ingredients, concentrations, etc.) from the workplace or manufacturer, and half 
could not identify the chemical class of the products in question.
Diagnostic tools, such as the skin prick test (SPT), intracutaneous testing, and specific IgE 
immunoassays can confirm sensitization but whether the agent(s) is responsible for causing 
symptoms needs to be correlated with exposure history and, when possible, confirmed by 
specific provocation. However, most chemicals related to causing or aggravating asthma are 
irritants and cannot be tested for causality using immunologic assessments. There are a 
number of key tools used in asthma evaluation, specifically spirometry and peak expiratory 
flow rate (PEFR) monitoring, but these tools have limitations. Sometimes patients do not 
show signs of reversibility and physicians must use non-specific provocation tests such as 
methacholine challenge to demonstrate airway hyperresponsiveness, a key feature of asthma 
related to smooth muscle dysfunction. Exhaled nitric oxide (NO), a non-specific 
measurement of inflammation, is another complementary, non-invasive test that is correlated 
with asthma control (Meyts et al., 2003). Although this tool may be a reliable predictor of 
poor asthma control based on symptoms, β-agonist use, and spirometry, physicians must 
interpret this test cautiously since inflammation does not always coincide or correlate with 
smooth muscle dysfunction.
The absence of chemical specificity of many existing diagnostic approaches has led to 
efforts to use controlled exposure chamber methods. Environmental exposure chambers can 
be used to expose patients to allergic and non-allergic asthma triggers (e.g., cold air; 
Bernstein et al., 2012). Responses are generally heterogeneous but these challenges can 
confirm what is learned from the patient’s history (Pfaar et al., 2017). In addition to research 
purposes, controlled challenges with specific suspected causative agents may also be 
considered in cases where there is diagnostic uncertainty due to a poor patient history, 
confounding factors, diagnostic disputes and for legal purposes.
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Despite the current availability of diagnostic tools, there is still a need for more research to 
better understand different asthma phenotypes/endotypes and pathomechanisms, specifically 
incorporating provocation studies to assess end organ reaction to environmental irritants in 
conjunction with ex vivo and in vivo cellular responses. If researchers can elucidate unique 
“endotypes” for asthma, biomarkers can be identified that will help better assess a patient’s 
potential for developing asthma in response to a spectrum of causal factors including 
chemical irritants.
Key Research Recommendations
• Understand mechanisms of asthma related to specific exposures including 
chemicals
• Define patient phenotypes based on existing clinical tools
• Integrate specific asthma phenotypes with pathomechanisms to define a 
unique asthma “endotype”
• Identify biomarkers that assess and differentiate irritant versus allergy-based 
asthma responses
• Access and apply advanced diagnostic approaches, including controlled 
challenges
The Role of Toxicology in Asthma Hazard Assessment
Asthma can be caused by both allergic and non-allergic mechanisms. There are two phases 
to allergies: an induction (or silent) phase and an elicitation phase involving manifestation of 
disease. Repeated exposures to proteins or chemicals with inherent respiratory sensitizing 
properties cause formation of antigens, induce the production of specific IgE, and prime 
tissue mast cells and basophils (induction) which results in clinical symptoms after 
continued or subsequent exposure (elicitation). Cross-over is limited between Type 1 (IgE 
mediated) responses (i.e., immediate allergic responses), which are more closely associated 
with respiratory allergy responses (e.g., sneezing, wheezing, and anaphylaxis) and Type 4 
(T-cell mediated) responses (i.e., delayed allergic responses) that are more closely associated 
with skin allergy responses (e.g., skin rashes and eczema). An argument has been made that, 
even for small molecules, IgE is the prevailing biological mechanism, although the presence 
or absence of antigen-specific IgE does not, alone, constitute causality or a lack thereof 
(Kimber et al., 2014). However, the detection of hapten-specific IgE for chemicals, as 
compared to protein allergens, may be much more difficult due to technical detection 
limitations, antibody distribution, and inability of clinical skin prick testing to recreate 
responses to past exposures.
Various predictive assays are used in the research context (e.g., guinea pig antigenicity test, 
guinea pig intratracheal instillation test, mouse intranasal test, structure activity relationships 
(SARs), mouse IgE tests, local lymph node assay (LLNA) and cytokine profiling, etc.) but 
remain unvalidated for use to detect respiratory sensitizers and are neither widely accepted 
nor used for hazard assessment purposes. Challenges remain in calibrating responses in in 
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vivo animal assays to human in vivo responses, in particular a lack of ability to predict 
potency. Additionally, quantitative SAR and mechanistic chemistry approaches have been 
explored (Dik et al., 2014), but such tools are limited for testing unknown or diverse 
chemicals that fall outside the training sets of substances. Biomarkers of asthma-like effects 
could also be monitored, specifically with chemicals that mimic haptens and form a 
complete allergen with endogenous proteins (e.g., trimellitic anhydride), and would provide 
longitudinal exposure information. In short, there are many useful tests or biomarkers for 
predicting and measuring asthma-related responses, but none can be used to identify or 
predict asthmatic responses, especially across the broad spectrum of asthmatic phenotypes.
Although currently available assays (e.g., SPT and LLNA) have limited utility in asthma risk 
assessment, there are a number of assays and tests in development that may be useful for 
predicting asthma (e.g., respiratory LLNA, SAR). However, development of a repeatable, 
validated, practical assay for asthma prediction is nascent and still substantially far from 
completion. Researchers have a robust, predictive, and accurate assay for predicting skin 
sensitization, the LLNA, but only because of the large body of clinical data used to validate 
the assay and its predictions. There is no equivalently robust dataset for development of 
respiratory sensitization assays, due to a combination of a lack of human data and avoidance 
of using animal models (e.g., Tox 21; NAS, 2017). There are in silico methods that permit 
consideration of the chemistry of particular compounds that are known to cause asthma (e.g., 
isocyanates) where we can make judgements by categorical classes based on chemical 
structure (e.g., Cramer classes; Cramer et al., 1978) in the absence of a sophisticated model. 
However, for respiratory sensitizers, current SAR models are not able to predict 
approximately 2/3 of the chemicals known to cause asthma, and inevitably new substance 
prediction is likely to be even less accurate (Dik et al., 2014). To move forward in assay 
development, we need a stronger understanding of the underlying biology and mode of 
action for both allergic and non-allergic asthma.
There are relationships between dermal sensitization in vivo tests and respiratory 
sensitization that can be used to inform risk assessments. To date, all known respiratory 
sensitizers are also dermal sensitizers, while the converse is not true; only a small minority 
(<1%) of dermal sensitizers are also respiratory sensitizers (Basketter and Kimber, 2016; 
Dearman et al., 2013). As a result, if one tests a compound using the validated in vivo skin 
assays and the result is negative, it is very unlikely the compound will be a respiratory 
sensitizer. However, if the same dermal tests yields a positive response, then the respiratory 
sensitization potential is uncertain and needs additional examination. Chemicals that cause 
allergic responses in skin and lung can be identified by cytokine fingerprinting (typically by 
examining the differential expression of IL4 vs IFNγ), which may help separate Th1 and 
Th2 cytokine mechanisms that are potentially indicative of skin versus respiratory 
involvement respectively (Dearman et al., 2003; De Jong et al., 2009; Kimber et al., 2007; 
Dearman et al., 2013). Skin, but not respiratory, sensitizers caused IL18 release from 
NCTC2544 cells (Corsini et al., 2009), but the method still awaits more formal validation. 
Genomic profiling approaches for identifying respiratory sensitizers are also in development 
(Dik et al., 2015).
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It is clear that some largely unknown, non-allergic mechanisms can generate bronchial 
hyperreactivity. There is well known evidence that high concentration exposures to bronchial 
and pulmonary irritants can produce RADS. Other non-allergic mechanisms can also 
provoke an asthmatic reaction in persons with hyperreactive airways. For example, fragrance 
factory workers do not a have an increased risk of occupational asthma, and persons with 
fragrance allergies, manifested as allergic contact dermatitis, almost never have respiratory 
effects even following airborne skin contact; nonetheless, fragrances have been shown to 
provoke asthmatic reactions (Basketter and Kimber, 2015). Translating current in vivo, in 
vitro, or in silico irritancy assays to asthma potency in a quantitative way has not been 
validated. An additional challenge is gaining an understanding of the basis for such asthma 
responses with low dose chronic exposures to irritants that are non-allergens (e.g., LICEDS, 
low-intensity chronic exposure dysfunction syndrome). In absence of detailed knowledge of 
the mode of action (MOA), one might consider that, from a risk and safety assessment 
perspective, a pragmatic management approach would be to avoid substantial irritant 
responses to reduce concerns about asthma responses.
In summary, respiratory allergy is a well characterized toxicology endpoint, and benchmark 
approaches are used to overcome a lack of reliable, validated predictive tests. Non-allergic 
asthma, however, has little information, no predictive tests, and no acceptable risk 
assessment methods for overcoming these data gaps. There may be ways to achieve useful, 
defensible safety assessment decisions to protect against non-allergic sensitization and 
asthma, but additional research is needed. Careful consideration must be given to whether 
current benchmarks are sufficiently protective, especially in the context of non-allergic 
asthma.
Key Research Recommendations
• Identify the multiple mechanisms, allergic and non-allergic, that cause asthma 
and develop molecular screening approaches to differentiate among these 
mechanisms
• Develop a validated predictive assay specific to respiratory sensitization
• Translate current in vivo, in vitro, or in silico irritancy assays to asthma 
potency in a validated, quantitative method
Assessing Exposure Contributions to Asthma Prevalence
Exposure science is the study of an organism’s contact with physical, chemical, biological 
and other agents in the environment. Exposure assessments are important – in part - because 
they provide the underpinnings for many of the health protective limits and risk management 
strategies set by public health and environmental regulatory agencies. Environmental 
epidemiological research examines links between exposures and human health outcomes, 
while risk assessments use the results of this type of research (along with that from 
toxicological and other studies) to develop characterizations of risk associated with specific 
exposures. Human health risk assessment uses hazard information, dose-response 
assessment and exposure assessment to determine a risk characterization, or probability of 
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an adverse health outcome occurring in an exposed population. These fields require robust 
assessments of exposure. The extent of exposure can be determined using an aggregate 
approach or cumulative approach. Aggregate exposure assessments evaluate exposures to a 
single chemical across multiple routes and pathways. Cumulative exposure evaluates 
exposure to multiple chemicals from multiple routes. Cleaning-related exposures are 
complex (Maier et al., 2015) and not well-characterized by exposure measurements of single 
chemicals or single products. Single products may include multiple chemicals, and multiple 
products are used over the course of cleaning durations. Moreover, impacts of non-chemical 
stressors (e.g., biological aerosols) may also modify asthmatic responses (Ross et al., 2000; 
Bush et al., 2006; Dick et al., 2014). An additional limitation relates to the extremely 
minimal amount of data available on specific cleaning agent exposures, especially in the 
context of asthma outcomes (Vandenplas et al., 2013).
Further issues associated with attempting to measure or model human exposures to cleaning 
agents and associated respiratory outcomes relate to the different populations of interest. For 
example, occupational exposure assessment may need to include worker use of protective 
equipment and regular long-term exposures in contrast with the more sporadic exposures 
assumed for non-occupational users. Exposure assessments must also consider differences in 
behavior, surface area, breathing rates, mouthing activities, etc. between children and adults. 
Other important exposure considerations are frequency of use (e.g., once, daily, weekly, 
repeated or continuous), type of application (e.g., wipes, sprays, waxes, liquids, particulates, 
or vapors), and the route of exposure (e.g., inhalation, dermal, or oral).
The three main approaches for quantitatively estimating exposure are direct measurements, 
indirect measurements, and use of exposure reconstruction with biomonitoring (U.S. EPA, 
2011, 2016). Direct (point of contact) measurements evaluate exposures in real time as they 
occur. This provides an exposure profile that yields information regarding temporal 
variability and peak exposures (e.g., Bello et al., 2010). Indirect estimation quantifies 
exposure by measuring or estimating the amount and frequency or duration of contact with a 
substance (U.S. EPA, 2011, 2016). This can be done using actual measurements, models or 
questionnaire data and combining this information with what is known about human activity 
to estimate exposure, as has been done with U.S. EPA’s superfund risk assessment guidance 
(U.S. EPA, 2004, 2009). Exposure reconstruction/biomonitoring approaches use internal 
body measurements to estimate dose. Advantages of this approach are that aggregate and 
cumulative exposures are accounted for and uptake and accumulation are considered. The 
limitations include cost and burden on study participants. A further issue is that collection of 
human matrices is often conducted a single time in a study, making it unclear whether the 
measurement is capturing a peak or other representation of exposure. Another difficulty with 
interpreting exposure reconstruction methods is that the data are not source- or pathway-
specific (U.S. EPA, 2011, 2016).
There are still too many gaps in understanding real-time exposure and, without continuous, 
real-time exposure monitoring, clinicians and researchers cannot truly understand the causal 
exposures needed to elicit respiratory effects. Although the technology is in place, direct, 
cumulative exposure measurements for quantitative, informative exposure estimation are 
costly and difficult to fund and implement. Researchers, therefore, frequently rely on clues 
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from epidemiological data and clinical information that may provide only a binary yes/no 
exposure characterization which is not translatable to dose. Improvements in, and increased 
use of sensor technology can advance our characterization of exposures. Ideally there could 
be individualized real-time exposure assessments in the future that can better capture 
exposure variability across a population and improve our understanding of individual 
exposure patterns and risks. Some of this technology is envisioned in the concept of the 
exposome (NRC, 2012).
As tools and methods for capturing improved exposure data are developed, care must be 
taken to ensure that high quality data are generated. For example, with the increased in use 
of biomonitoring as a measurement gold standard, researchers assumed the method would 
capture the totality of exposure across routes. We now know, however, that biomarker data 
are much more complicated in interpretation (i.e., some data need adjustment for additional 
factors such as urinary dilution) and susceptible to contamination from unexpected sources 
(i.e., leaching of plastic from storage containers into the samples; Blount et al., 2010). It is 
important that we validate the data we are collecting, and understand the quality of the data 
and its strengths and limitations (LaKind et al., 2014).
Exposure information is critical for dose-response assessment, yet it is difficult to obtain the 
kind of data needed on cleaning products due to resource and time restraints. Although it 
may be impossible to get funding for a perfect study, we have multiple tools available that 
ensure exposure data represent actual exposures at relevant times. High quality exposure 
information will aid in interpreting associations reported in epidemiological research and to 
support risk assessment for cleaning-related activities and products.
Key Research Recommendations
• Gather information on specific cleaning agent exposures, especially in the 
context of asthma outcomes, to aid development of a robust exposure 
assessment
• Address population variability which prevents generalization of measured or 
modeled human exposures
• Identify methods for reducing the prohibitive costs and volunteer participation 
needs for obtaining robust exposure data that incorporates temporality
Setting Exposure Limits for Chemical Allergens
Chemical allergens are typically categorized by their molecular weight (i.e., high molecular 
weight (HMW) versus low molecular weight (LMW) allergens). HMW allergens (e.g., 
animal and plant proteins, latex, enzymes) are directly recognized by the immune system. 
LMW allergens (e.g., diisocyanates, organic anhydrides, some metals) are highly reactive 
and electrophilic, but are so small that they must bind with an endogenous protein to be 
recognized by the immune system. In 2016, approximately 6–7 hundred compounds have 
Threshold Limit Values (TLVs©) established by the American Conference of Governmental 
Industrial Hygienists (ACGIH©), despite the observation that many additional chemicals 
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can induce allergic sensitization. Many others are based on upper respiratory tract irritation, 
but the degree to which asthma responses were explicitly considered is unclear. The 
portfolio of health-based limits suggests significant uncertainty in relying on OELs for risk 
assessment and management of occupational asthma.
An understanding of basic biological mechanisms is needed so that risk assessors can 
appropriately select critical health endpoints for risk assessment. Ideally risk assessors could 
prevent sensitization, which would subsequently prevent elicitation. However, a portion of 
the population is already sensitized and it would be theoretically more health protective to 
prevent the elicitation of allergic responses in these individuals. Endpoints under 
consideration as the basis of risk assessment efforts and potentially capable of identifying 
persons who are in the process of being sensitized include: 1) lymphocyte proliferative 
responses, 2) changes in cytokine expression, 3) IgE antibodies, and 4) chemical challenges 
(e.g., patch test) (Cochrane et al., 2015). Because the biological response is complex 
(sensitization vs elicitation) and potency is difficult to estimate in a dose-response context, 
setting quantitative OELs has been limited primarily to chemicals with significant 
epidemiological data.
Exposure patterns are also important to consider for risk assessment, specifically temporal 
patterns. Exposure data are scarce for chemical allergens so it is unclear whether longer-
term,, short-term (peak) exposures, or both are the driver for sensitization. This information 
informs whether ceiling or TWA exposure limits should be used. For example, enzyme 
research was previously used to indicate that peak exposures were responsible for induction 
of sensitization (Basketter et al., 2012), which corresponds with our understanding of non-
linear (threshold) dose-responses. However, current research indicates that reality is much 
more complicated; in an enzyme factory, the prevalence of workers with specific IgE levels 
indicating sensitization is approximately 10%, but only 1% or lower exhibit symptoms 
(Basketter et al., 2015), which suggests that a higher concentration is possibly needed to 
elicit a response rather than induce sensitization. There are clearly some aspects of the 
exposure-response relationship that we are failing to understand, however, key experiments 
cannot be conducted, due to a lack of reliable assays and ethical considerations. Even real-
time exposure monitoring is not useful for answering this question unless biomarkers are 
also measured in real-time, otherwise response is not truly understood in the context of the 
exposure.
The impact of aggregate exposures (i.e., single exposures from multiple routes) also needs to 
be considered. For chemical allergens, there is a potential crossover between inhalation and 
dermal exposures, with the possibility that asthma may be induced by dermal exposure with 
elicitation occurring following a much lower inhalation dose. If dermal exposure potential is 
not considered, the application of derived exposure limits may not be sufficiently protective. 
Our inability to characterize the exposure-response relationship for both sensitization and 
allergic responses, including asthma, coupled with a poor understanding of cross-route 
mechanisms are the primary barriers to asthma risk assessment. In theory, if we could 
overcome these barriers we would be capable of assessing the risk for airway sensitization 
and immune-mediated asthma that also take other routes of exposures (e.g., dermal) into 
consideration.
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Until a respiratory equivalent to the dermal LLNA or other accepted assays is developed and 
validated, quantitative risk assessments used to develop exposure recommendations 
applicable to occupational and non-occupational settings for chemical allergens are likely to 
be limited. The current barriers are 1) identifying respiratory allergens, 2) finding well-
validated bioassays that provide dose-response information for multiple classes of 
chemicals, 3) differentiating between immune-mediated versus non-allergic asthma, 4) 
understanding short- and long-term and well as peak and background exposures, and 5) 
understanding the relative contributions of dermal and respiratory exposures on asthma 
response. The current science is not adequate to provide such data for most chemicals.
For chemical allergens with OELs, the exposure recommendations tend to be based on 
extensive human exposure data sets and are often based on sensitive subpopulations. In the 
absence of such quantitative health-based limits, qualitative hazard designations and risk 
management tools for exposure control are often used. Several sources of information 
provide useful guidance. The Globally Harmonized System for Labeling and Classification 
of Chemicals (GHS) provides qualitative sensitization designations for both respiratory and 
dermal sensitizers (UN, 2011). The National Institute for Occupational Safety and Health 
(NIOSH) and ACGIH also use similar designations to warn against the potential of dermal 
sensitization (NIOSH, 2009; ACGIH, 2016). Hazard-based systems can be included in 
hazard banding tools used to categorize available data into risk categories that drive control 
strategy selection (Arnone et al., 2015; Scheffers et al., 2016).
For risk assessment purposes, in the absence of chemical-specific dose-response 
information, a benchmarking based approach can be used to assess the need for tighter 
exposure control. Such approaches have been used successfully to manage respiratory 
sensitization in industries that handle enzymes (Basketter et al., 2015). Similar approaches 
might be applicable to chemical asthmagens such as diisocyanates and acid anhydrides. Use 
of these benchmarks should be done with caution, and a margin of error should be applied. If 
exposure levels are close to estimated exposure limits for occupational respiratory allergens, 
then further evaluation is needed. These approaches, when coupled with a comprehensive 
risk management approach (e.g., medical monitoring and surveillance, substitutions, 
engineered processes, etc.), can be used to mitigate risk when the available data is too 
limited or uncertain for a quantitative risk assessment.
Key Research Recommendations
• Understand the underlying biology of sensitization and the pathways that 
cause induction and elicitation of responses to support quantitative dose-
response prediction
• Determine the impact of temporal and route-dependent exposure patterns on 
asthma induction and response elicitation
• Refine and communicate risk management tools based on hazard related 
information
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Conclusions on Asthma-Specific Risk and Characterization
This brief review paper has described key challenges and research opportunities that will 
enable us to continue to enhance processes for assessing potential risk related to asthma and 
handling of consumer product chemicals.
A number of ways to assess chemical exposures and asthma and related endpoints (i.e., 
sensitization, irritation, and inflammation potentials) were described. Routine clinical and 
validated toxicological tests as well as exposure assessment approaches are not currently 
sufficiently robust for predicting or determining causal dose-response relationships between 
exposures and asthma induction. There are multiple barriers to assigning causality and 
understanding risk in clinical or risk assessment settings, specifically a lack of diagnostic 
tools or tests that can encompass the multiple diverse etiologies of asthmatic responses and a 
lack of robust exposure measurements that capture exposure patterns over time.
The limitations in our understanding of asthma etiology and biological mechanisms, 
together with a lack of validated predictive assays for assessing asthma induction or 
elicitation, require the use of alternative hazard-based safety assessment methods to address 
chemical-induced asthma risks when making decisions proactively. A toolkit has been 
proposed for safety assessment to provide a health-protective screening method that utilizes 
weight-of-evidence principles for identifying chemicals that may increase asthma risk 
(Maier et al., 2015; Vincent et al., 2016). This systematic approach used in conjunction with 
an active risk management program provides a mechanism to limit potential asthma 
concerns, identify any concerns that arise, and ensures deployment of an approach to 
mitigate asthma-related risks.
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